DK1905452T3 - Middel til forebyggelse eller behandling af glaukom - Google Patents

Middel til forebyggelse eller behandling af glaukom

Info

Publication number
DK1905452T3
DK1905452T3 DK06780961.6T DK06780961T DK1905452T3 DK 1905452 T3 DK1905452 T3 DK 1905452T3 DK 06780961 T DK06780961 T DK 06780961T DK 1905452 T3 DK1905452 T3 DK 1905452T3
Authority
DK
Denmark
Prior art keywords
preventing
treating glaucoma
glaucoma
treating
Prior art date
Application number
DK06780961.6T
Other languages
English (en)
Inventor
Ken Mizuno
Jiro Matsumoto
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of DK1905452T3 publication Critical patent/DK1905452T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06780961.6T 2005-07-12 2006-07-11 Middel til forebyggelse eller behandling af glaukom DK1905452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005203352 2005-07-12
PCT/JP2006/313740 WO2007007737A1 (ja) 2005-07-12 2006-07-11 緑内障を予防又は治療する薬剤

Publications (1)

Publication Number Publication Date
DK1905452T3 true DK1905452T3 (da) 2013-07-01

Family

ID=37637126

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06780961.6T DK1905452T3 (da) 2005-07-12 2006-07-11 Middel til forebyggelse eller behandling af glaukom

Country Status (11)

Country Link
US (1) US8193193B2 (da)
EP (1) EP1905452B1 (da)
JP (1) JP4972552B2 (da)
KR (1) KR101333990B1 (da)
CN (1) CN101198355B (da)
DK (1) DK1905452T3 (da)
ES (1) ES2416334T3 (da)
HR (1) HRP20130876T1 (da)
PL (1) PL1905452T3 (da)
PT (1) PT1905452E (da)
WO (1) WO2007007737A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932841B1 (en) 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
US8232292B2 (en) 2007-07-02 2012-07-31 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
JPWO2012105674A1 (ja) * 2011-02-04 2014-07-03 興和株式会社 緑内障予防又は治療のための薬物療法
JP2013129605A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する安定なフィルム製剤
JP2013129604A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する徐放性フィルム製剤
JP2015229671A (ja) * 2014-06-06 2015-12-21 株式会社デ・ウエスタン・セラピテクス研究所 網膜色素上皮細胞保護剤
CN106604730B (zh) * 2014-09-24 2019-12-20 兴和株式会社 角膜厚度调节剂
US10376523B2 (en) 2014-09-25 2019-08-13 Kowa Company, Ltd. Aqueous composition containing ripasudil, or a salt, or a solvate thereof
PT3199161T (pt) * 2014-09-25 2022-02-08 Kowa Co Preparação farmacêutica
KR20160108121A (ko) * 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
TWI699207B (zh) * 2015-08-31 2020-07-21 日商興和股份有限公司 拉巴斯吉之用於製造眼壓下降增強劑之用途
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
AU2024352423A1 (en) 2023-09-28 2026-05-14 Graviton Pharmaceuticals B.V. Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US3885047A (en) * 1972-06-16 1975-05-20 Mead Johnson & Co Ocular hypotensive process employing dextrorotatory phenethanolamines
US4483864A (en) * 1983-02-04 1984-11-20 University Of Iowa Research Foundation Non-classical topical treatment for glaucoma
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4797413A (en) 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
WO1999020620A1 (en) * 1997-10-22 1999-04-29 Nippon Shinyaku Co Ltd Isoquinoline derivative and drug
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
CA2635412C (en) 1998-08-17 2011-06-21 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of asthenopia or pseudomyopia
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
KR100818061B1 (ko) 2000-03-16 2008-04-01 미쯔비시 웰 파마 가부시키가이샤 아미드 화합물 및 그의 용도
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
US7442686B2 (en) * 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
EP1455795A1 (en) * 2001-12-12 2004-09-15 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
JP2005533055A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド 新規マキシｋチャンネルブロッカー、その使用方法および製造方法
JP4482726B2 (ja) 2002-08-29 2010-06-16 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
JP2004250410A (ja) 2003-02-21 2004-09-09 Mitsubishi Pharma Corp 腎臓における虚血−再灌流障害の治療剤
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2005034866A2 (en) 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
JP4764823B2 (ja) 2003-10-06 2011-09-07 グラクソ グループ リミテッド キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
WO2005099691A1 (en) * 2004-03-31 2005-10-27 Pharmacia & Upjohn Company Llc Composition for treating elevated intraocular pressure
US20080097108A1 (en) * 2004-10-13 2008-04-24 Ying-Duo Gao Ophthalmic Compositions for Treating Ocular Hypertension
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma

Also Published As

Publication number Publication date
CN101198355B (zh) 2010-11-10
WO2007007737A1 (ja) 2007-01-18
KR20080027827A (ko) 2008-03-28
JPWO2007007737A1 (ja) 2009-01-29
PL1905452T3 (pl) 2013-11-29
KR101333990B1 (ko) 2013-11-27
PT1905452E (pt) 2013-07-16
US8193193B2 (en) 2012-06-05
US20090118299A1 (en) 2009-05-07
ES2416334T3 (es) 2013-07-31
JP4972552B2 (ja) 2012-07-11
EP1905452B1 (en) 2013-06-19
HRP20130876T1 (hr) 2013-10-25
CN101198355A (zh) 2008-06-11
EP1905452A4 (en) 2012-02-15
EP1905452A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
EP1935588A4 (en) SHAVER
PL1858917T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
ITMO20050327A1 (it) Mola perfezionata
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK2110141T3 (da) Middel til beskyttelse af retinalnerve eller synsnerve
DK1856024T4 (da) Fremgangsmåde til fremstilling af substituerede biphenyler
DK1846354T3 (da) Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande
NL1036308A1 (nl) Lithographic method.
DK1992352T3 (da) Middel til anvendelse i forbyggelsen af aterosklerosis
DE502006007466D1 (de) Laser-Mikrodissektionsgerät
EP1853274A4 (en) 2-METHYLENE-19-NOR- (20S-24S) - 1ALPHA, 25-D HYDROXYVITAMINE-D2
DK4070800T3 (da) Cladribinkur til behandling af multipel sklerose
NO20082650L (no) Benzenderivat eller salt derav
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
DK2366393T3 (da) Roflumilast til behandlingen af pulmonal hypertension
NO20053226D0 (no) Fremgangsmate for elektrokinetisk migrasjon.
ES1059722Y (es) Cuerda para elementos de proteccion individual.
DK1933861T3 (da) Fremgangsmåde til behandling eller forebyggelse af multiorgansvigt
FI20080436L (fi) Terä
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK1931618T3 (da) Fremgangsmåde til fremstilling af aniliner
FR2891181B1 (fr) Dispositf pour la fente de buches
ITPN20050088A1 (it) Cabina attrezzata per doccia.